Lifecome Biochemistry Co Ltd

Lifecome Biochemistry Co Ltd has a market price of 36.34 CNY and a market capitalization of 5,647,811,516.58 CNY, indicating a high valuation relative to its tangible book value of 89.39. The company's liquidity is rated as medium, with a current ratio of 0.35, suggesting limited short-term liquidity to cover its liabilities. The enterprise value to revenue ratio is 12.03, and the enterprise value to EBITDA ratio is -47.95, reflecting a negative EBITDA and a high valuation relative to its revenue. The company's profitability is weak, with a return on equity of -2.1963% and a return on assets of -0.1853%, both significantly below industry norms. The net income is negative at -138,758,630 CNY, and the operating income is also negative at -129,576,630 CNY, indicating operational inefficiencies and financial distress. The gross profit of 15,177,370 CNY is minimal compared to the company's revenue of 516,580,140 CNY, suggesting high cost structures and low margins. Lifecome Biochemistry Co Ltd's revenue is not segmented by geographic regions or product lines in the available data, making it difficult to assess geographic or segment concentration risks. The company's total assets are 748,708,860 CNY, while its total liabilities are 685,529,700 CNY, resulting in a debt-to-equity ratio of 8.94, which is very high and indicates significant leverage. The company's growth trajectory is uncertain, with no specific outlook provided for the current or next fiscal year. The operating cash flow is negative at -25,078,450 CNY, and the free cash flow is also negative at -212,946,290 CNY, indicating a lack of cash generation and potential liquidity constraints. The capital expenditure of -129,800,720 CNY suggests ongoing investment, but the negative cash flows raise concerns about the sustainability of these investments. The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The key financial flag is the negative net cash position after subtracting total debt, which highlights the company's financial instability. The high debt-to-equity ratio and negative cash flows suggest a high risk of financial distress and potential need for further financing, which could lead to dilution. Recent events and filings do not provide specific details on the company's strategic initiatives or financial developments. The lack of detailed information on recent events and the company's financial health makes it challenging to assess its future prospects and risk profile.